Carotid Endarterectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid endarterectomy (CEA) is the open surgical procedure in which atherosclerotic plaque obstructing the internal carotid artery at the carotid bifurcation is surgically removed to restore normal luminal diameter, eliminate the embolic source for TIA and stroke, and reduce the haemodynamic impact of critical stenosis. It is one of the most thoroughly evaluated surgical procedures in medicine, underpinned by the NASCET, ECST, and VACSP randomised trials that collectively enrolled over 6,000 patients and established its superiority over medical therapy for symptomatic 70–99% stenosis.

The operation begins with a longitudinal incision along the anterior border of the sternocleidomastoid muscle in the neck, exposing the carotid sheath and bifurcation. The common carotid, internal carotid, and external carotid arteries are individually controlled with vascular clamps. An arteriotomy is made through the plaque, and the atherosclerotic material — typically a hard, yellowish lipid-fibrous-calcified core adherent to the arterial wall — is carefully dissected and removed in a single piece, taking care to tack down any distal intimal flap to prevent post-operative thrombosis. The arteriotomy is then closed with either direct suture (rarely used now due to restenosis risk) or a patch of bovine pericardium, PTFE, or saphenous vein to widen the repaired segment and minimise restenosis.

The operation takes 60–90 minutes, is performed under general or local anaesthesia, and requires one to two nights of post-operative monitoring. The perioperative stroke and death rate at specialist centres is below 3%, making the risk-benefit ratio highly favourable for symptomatic high-grade stenosis.

Symptomatic carotid stenosis is the dominant indication — specifically ipsilateral internal carotid stenosis above 50% (by NASCET criteria) in patients with recent TIA or minor ischaemic stroke within the past six months. The evidence for benefit is strongest for 70–99% stenosis (17% absolute risk reduction in five-year ipsilateral stroke), moderate for 50–69% stenosis (benefit depends on clinical factors including gender, age, degree of stenosis), and absent for stenosis below 50%. Amaurosis fugax — transient monocular blindness from ophthalmic artery emboli arising from ipsilateral carotid plaque — is an equivalent indication to hemispheric TIA.

Asymptomatic stenosis above 60–70% is a secondary indication for selected patients at low surgical risk with life expectancy above five years. The ACST trial demonstrated a 5.4% absolute five-year reduction in stroke in surgically treated asymptomatic patients. High-risk features that favour intervention in asymptomatic patients include contralateral carotid occlusion, silent ipsilateral ischaemic brain lesions on MRI, and stenosis that is rapidly progressing. The ongoing CREST-2 and ECST-2 trials are evaluating whether modern optimal medical therapy alone is sufficient for asymptomatic patients, results of which will refine future guidelines.

Ideal candidates are patients aged under 80 years (physiological age matters more than chronological age) with recently symptomatic ipsilateral stenosis above 50%, modified Rankin Scale score of 3 or less (functionally independent), acceptable perioperative surgical and anaesthetic risk, and no contraindication to antiplatelet therapy. The key principle of patient selection is that the benefit of surgery must substantially outweigh the risk: the five-year absolute benefit of 17% for 70–99% symptomatic stenosis requires that the perioperative stroke and death rate at the operating centre is below 6%. Centres should prospectively audit and publish their own CEA outcomes.

Absolute contraindications include complete carotid occlusion (no lumen accessible for endarterectomy), major hemispheric infarction with dense deficit within the preceding four to six weeks (risk of haemorrhagic transformation), life expectancy below two years from malignancy or other comorbidity, and active systemic infection. Relative contraindications include high cervical carotid bifurcation (above C2), severe concurrent cardiac disease requiring prioritised treatment, and poor contralateral collateral reserve raising the risk of hypoperfusion during clamping.

Conventional carotid endarterectomy with patch closure is the gold-standard technique. Randomised trials comparing patch closure to primary closure demonstrate significantly lower restenosis and re-occlusion rates with patch closure. Bovine pericardial patch is favoured at many centres due to its handling properties and low infection risk; PTFE patch is an alternative; autologous saphenous vein patch has the lowest infection rate but requires additional harvesting. Eversion endarterectomy — transecting the ICA and everting the plaque from the arterial wall — provides equivalent long-term outcomes, shorter clamp times, and no need for patch material, but requires specific technical training.

Intraoperative cerebral monitoring during carotid clamping — via TCD middle cerebral artery flow velocity, SSEPs, NIRS near-infrared spectroscopy, or awake neurological assessment under local anaesthesia — guides selective shunt usage. Routine shunting exposes all patients to the technical complications of shunt insertion; selective shunting based on monitoring criteria protects patients with poor collateral reserve while avoiding unnecessary shunt use. Carotid artery stenting (CAS) remains the main procedural alternative, preferred for anatomically high-risk surgical necks, prior radiation therapy, contralateral nerve injury, and high surgical cardiac risk. Transcervical carotid artery stenting with flow reversal (TCAR) is an emerging alternative for high surgical risk patients with favourable anatomy — including hostile surgical necks, prior radiation therapy, contralateral nerve injury, and high surgical cardiac risk. Regional anaesthesia allows neurological monitoring during cross-clamp and reduces cardiovascular complications in comparative trials.

In symptomatic patients with 70–99% stenosis, five-year absolute risk reduction in ipsilateral stroke or perioperative death is 15–17% compared to medical therapy alone (NASCET data). The number needed to treat is approximately six patients to prevent one stroke over five years — an exceptional surgical treatment efficiency. The benefit peaks when surgery is performed within two weeks of the index TIA or minor stroke, and clinical evidence strongly supports urgent rather than deferred CEA. For 50–69% stenosis, benefit is more modest and depends on clinical characteristics (greater benefit in males, older patients, and those with recent rather than remote symptoms).

Long-term results after successful CEA are excellent: restenosis above 50% occurs in only 5–10% of patients at ten years (lower with patch closure), and recurrent ipsilateral neurological events are uncommon once the endarterectomised segment remains patent. Patient reported outcomes consistently demonstrate improved quality of life related to resolution of stroke-related anxiety and return to normal activities. The psychological benefit of definitive plaque removal — versus ongoing concern about an untreated embolic source — is an underappreciated benefit of surgery.

Perioperative stroke is the critical risk — occurring in 1.5–3% of patients at experienced centres. Ipsilateral stroke during or immediately after CEA may be embolic (plaque fragments during dissection, thrombosis at the endarterectomised site), haemodynamic (inadequate collateral during clamping), or due to carotid artery thrombosis early post-operatively. Perioperative death occurs in 0.5–1.5% overall, most commonly from cardiac events reflecting the high cardiovascular risk profile of carotid atherosclerosis patients. Cerebral hyperperfusion syndrome — sudden ipsilateral headache, seizures, and focal neurological deficit from vasodilatory breakthrough in a chronically ischaemic hemisphere — occurs in 1–3% and requires aggressive blood pressure management (labetalol infusion, avoid anticoagulation for 24–48 hours).

Cranial nerve injuries are the most frequent complication: hypoglossal nerve injury (tongue deviation, mild dysarthria) in 5–8%, vagus/recurrent laryngeal nerve injury (hoarseness) in 3–5%, and marginal mandibular branch facial nerve injury (lower lip asymmetry) in 2–3%. The vast majority are neurapraxia — temporary injury from stretch or retraction — that resolves within weeks to months; permanent nerve injury occurs in below 1%. Wound haematoma requiring surgical evacuation affects 2–5% of patients and can be life-threatening if airway compromise results from rapid haematoma expansion — reason for 12–24 hours of closely monitored post-operative observation.

Post-operative management focuses on neurological status monitoring every 30 minutes for the first 12–24 hours, blood pressure control (avoiding both hypertension above 180 systolic and hypotension below 100 systolic), and haematoma vigilance. Aspirin is resumed as soon as post-operative haemostasis is established. Discharge on day one to two with oral antiplatelet therapy (aspirin ± clopidogrel), high-intensity statin (atorvastatin 40–80 mg), antihypertensives, and any other cardiovascular medications. Patients with residual neurological deficit from a pre-operative stroke are referred to the neurorehabilitation team.

Return to driving occurs at two to four weeks for patients who experienced a TIA (national guidelines vary); patients with a recent stroke face longer restrictions (one month minimum; up to three months for significant deficit). Duplex ultrasound surveillance of the operated carotid is recommended at one month, six months, and annually. High-intensity statin therapy is maintained indefinitely to prevent plaque progression in the contralateral carotid and coronary arteries. Target blood pressure below 130/80 mmHg is maintained lifelong. Smoking cessation is the single most impactful lifestyle modification for long-term cardiovascular event prevention.

Carotid endarterectomy in the United States costs USD 20,000–50,000 for the entire episode of care including pre-operative imaging, surgical fees, anaesthesia, hospitalisation, and post-operative monitoring. UK NHS performs CEA without direct cost for eligible patients; private CEA in the UK costs GBP 8,000–18,000. In India, Apollo Hospitals, Fortis, Narayana Health, and Manipal Hospitals perform high-quality CEA at total costs of USD 3,000–7,000 — a saving of 85–90% versus US prices. Thailand (Bumrungrad International) charges USD 8,000–15,000; Turkey (Acibadem) USD 5,000–12,000; Poland USD 4,000–8,000.

The short hospital stay (one to two days) and rapid recovery make international CEA logistically straightforward for medically stable patients requiring elective intervention for asymptomatic or recently stabilised symptomatic stenosis. Patients should confirm the centre's vascular surgery team performs high-volume CEA (the optimal annual volume threshold is above 50 cases per surgeon), has intraoperative neuromonitoring capability, and provides post-discharge stroke physician follow-up. Pre-operative duplex ultrasound and CT angiography should be performed at the destination centre to validate stenosis severity before proceeding.

Carotid artery stenting (CAS) is the principal procedural alternative to CEA, with equivalent overall outcomes for patients under 70 years with anatomical contraindications to surgery. CAS is preferred in patients with prior ipsilateral neck surgery or radiation, high cervical bifurcation, contralateral cranial nerve palsy, and cardiac contraindications to general anaesthesia. The CREST trial demonstrated that CEA and CAS have equivalent composite four-year outcomes for stroke, MI, or death in symptomatic patients, but with different complication profiles: CAS has higher peri-procedural stroke rates in older patients, while CEA has higher rates of minor MI and cranial nerve injury. Optimal medical therapy alone is appropriate for low-grade stenosis, asymptomatic disease below 60%, and surgical contraindications.